Sino Biopharmaceutical Limited

Equities

1177

KYG8167W1380

Pharmaceuticals

Market Closed - Hong Kong S.E. 09:08:27 12/07/2024 BST 5-day change 1st Jan Change
2.89 HKD +2.12% Intraday chart for Sino Biopharmaceutical Limited +2.12% -16.71%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sino Biopharmaceutical Gets NMPA's Nod for Marketing Diabetes Drug MT
Sino Biopharmaceutical Limited Receives Approval for Marketing of Liraglutide Injection CI
Sino Biopharmaceutical Completes Issuance of 1.5 Billion Yuan in Panda Bonds MT
Sino Biopharmaceutical Completes Issuance of 1.5 Billion Panda Bonds MT
Sino Biopharmaceutical Gets Marketing Go-Ahead for Lung Cancer Drug in China MT
Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Innovative Drug Envonalkib Citrate Capsules "Envonalkib (TQ-B3139)" CI
Sino Biopharm Trustee Purchases 15.8 Million Shares Under Incentive Scheme MT
Sino Biopharmaceutical Gets Marketing Go-Ahead for MRI Contrast Agent from Chinese Regulator MT
Sino Biopharmaceutical Limited Announces Approval for Marketing of Gadoteridol Injection CI
Sino Biopharmaceutical's Phase 2 Trial Results of Lung Cancer Tablet Published in Medical Journal MT
Sino Biopharmaceutical Limited Announces Publication of Study Findings of Phase II Clinical Trial of KRAS G12C Inhibitor "Garsorasib (D-1553) in the Lancet Respiratory Medicine CI
Sino Biopharmaceutical Limited Announces KRAS G12C Inhibitor Garsorasib Tablet (D-1553) Included in the Breakthrough Therapeutic Designation Process CI
Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic RE
Sino Biopharmaceutical Presents Findings of Anti-Tumor Drug at American Cancer Conference MT
Sino Biopharmaceutical Cuts Conversion Price of Euro-Denominated Bonds Due 2025 MT
Sino Biopharmaceutical Limited Announces Retirement of Ms. Li Mingqin as Executive Director CI
Sino Biopharmaceutical's Renal Cancer Combination Treatment Shows Promise in Phase III Trials MT
Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for First-Line Treatment of Advanced Renal Cell Carcinoma CI
Sino Biopharmaceutical's Novel Lung Cancer Drug Approved in China; Shares Up 5% MT
Sino Biopharmaceutical Limited Receives Marketing Approval from National Medical Products Administration of China CI
Wall Street, Earnings, Federal Reserve Roil Asian Stock Markets MT
Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Unecritinib Fumarate Capsules CI
Sino Biopharm Completes Phase I Study of Hepatitis B Drug MT
Lull in Geopolitical Tensions Lifts Asian Stock Markets MT
Hong Kong shares jump on policy support; China slips RE
Chart Sino Biopharmaceutical Limited
More charts
Sino Biopharmaceutical Limited specialises in the development, manufacture and marketing of biopharmaceutical products primarily for the treatment of cancer, ophthalmia, hepatitis, orthopedic diseases and respiratory disorders. Net sales break down by category of products as follows: - chemical medicine products and biopharmaceutical drugs (97.6%); - other (2.4%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
2.631 CNY
Average target price
4.253 CNY
Spread / Average Target
+61.66%
Consensus
  1. Stock Market
  2. Equities
  3. 1177 Stock
  4. News Sino Biopharmaceutical Limited
  5. Sino Biopharmaceutical Completes Issuance of 1.5 Billion Yuan in Panda Bonds